Aspirin Use in Heart Failure

Aspirin for heart failure: theory- or evidence-based?

Beta-blocker use in decompensated heart failure.

Despite the current advances in treatment, acute decompensated heart failure accounts for more than 1 million hospital admissions annually. Many of the patients hospitalized are already receiving long-term treatment with beta-blockers. For patients who receive full dose beta-blocker therapy and suffer acute decompensated heart failure, clinicians face two key questions: what to do, if anything,...

Biomarkers in heart failure: ready for use?

Use of placebo in heart failure research.

To the Editor: The recently published Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH), a multinational study of 844 patients with class II to III systolic congestive heart failure (CHF), investigated the effects of the angiotensin II receptor blocker candesartan cilexetil on exercise time and the signs and symptoms of CHF.1 In the 59% of pat...

Aspirin use in heart failure: is low-dose therapy associated with mortality and morbidity benefits in a large community population?

Background- Aspirin use in heart failure (HF) is controversial. The drug has proven benefit in comorbidities associated with HF; however, retrospective analysis of angiotensin-converting enzyme inhibitor trials and prospective comparisons with warfarin have shown increased risk of morbidity with aspirin use. This study aims to evaluate the association of low-dose aspirin with mortality and morb...